Fresh off a $275 million fundraise—the largest in digital health so far this year—Innovaccer’s cofounder and CEO Abhinav Shashank has a plan to pull together data and AI tools all in one place..| Forbes
Medallion is setting up a national clearinghouse to streamline a healthcare credentialing process that costs more than $1 billion annually.| Forbes
What if dogs could live longer and healthier lives? Loyal’s Celine Halioua has raised $135 million from top investors to develop canine longevity pills—and expects to get her first conditional approval from the FDA next year.| Amy Feldman
This Forbes list highlights 25 venture-backed companies likely to become unicorns. Learn more about the founders and investors behind these fast-growing tech startups.| Amy Feldman
For years, Jake Becraft has been working at the bleeding edge of cancer research. Now, with solid early clinical results and a boatload of cash he’s hoping to bring his first innovative therapeutic to market by 2030.| Amy Feldman
Longtime drug developer Suma Krishnan was 51 when she cofounded Krystal Biotech. Now the company has one gene therapy on the market and more in the works.| Forbes
With no exemptions for medical devices from Trump’s double-digit tariffs, pacemakers, insulin pumps and hearing aids could all cost more.| Forbes
Daniel Nadler started OpenEvidence to help physicians sort through a deluge of medical research. Now, he’s raised $210 million at a $3.5 billion valuation.| Forbes
It’s still much more expensive to get stuff to the U.S. from Asia a year after shipping costs first shot up.| Forbes
Commercial beekeepers saw well over 50% losses this winter. As California prepares for almond season, and for fruits like blueberries and cherries after that, not enough bees could mean higher prices at the grocery store.| Forbes
New drugs take too long to get to market because of clinical trial bottlenecks. Two cancer doctors built AI-enabled tech to speed up the process.| Amy Feldman
Millions of people get cataract surgery every year. Startup ForSight, backed with $125 million in fresh funding, is betting a robot can do it better than humans.| Forbes
The supply chain is scrambling to rid itself of ‘forever chemicals’ before restrictions take effect in California and other states.| Forbes
The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.| Forbes
Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug powerhouse and has become one of the world’s most successful female entrepreneurs.| Forbes
Since the start of the pandemic, the popular medical device has been indispensable for measuring oxygen in the blood, but dangerously inaccurate in patients with darker skin. Now the FDA is in the hot seat and Black researchers are working on a cure.| Forbes
Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is quickly emerging as a powerhouse pharmaceutical R&D center.| Forbes
Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations more efficient. But most of the best data scientists aren’t working in healthcare—at least not yet.| Forbes
Startup K Health’s AI physician assistant matched doctors’ clinical decisions in two-thirds of patient cases, while offering better care in the remaining third, according to a new study from researchers at Cedars-Sinai, Tel Aviv University and K Health.| Forbes
Former Palantir employees Mayank Jain and Pranav Pillai started Guardian AI to help healthcare providers fight insurance claim denials. Now their former employer is suing them for allegedly stealing trade secrets.| Forbes
Khosla-backed Gather Health has signed up more than 2,500 patients, the majority on both Medicare and Medicaid, for its primary-care service. With $17 million in new funding, it’s growing fast—and expects to reach breakeven on its four centers this year.| Forbes
Colossal Biosciences cofounder and CEO Ben Lamm is worth $3.7 billion following the company's recent fundraise at an eye-popping $10.2 billion valuation. But it has yet to be paid for reviving extinct animals or saving endangered ones.| Forbes
